<DOC>
	<DOCNO>NCT02616783</DOCNO>
	<brief_summary>This study evaluate safety elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide ( E/C/F/TAF ) relative unchanged current antiretroviral therapy ( ART ) assess spine hip bone mineral density ( BMD ) measure Week 48 virologically-suppressed , HIV-1 infect participant age ≥ 60 year .</brief_summary>
	<brief_title>Switching From Tenofovir Disoproxil Fumarate ( TDF ) Containing Regimen Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide ( E/C/F/TAF ) Fixed-Dose Combination ( FDC ) Virologically-Suppressed , HIV-1 Infected Adults Aged ≥ 60 Years</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Key Currently receive TDF FTC 3TCcontaining 'backbone ' ( maximum 2 NRTIs ) regimen plus third agent ≥ 6 consecutive month prior screen visit . For individual 3 ART regimen , regimen history must provide approval Sponsor . Refer assign intervention allow third agent current regimen . Documented plasma HIV1 RNA level &lt; 50 copies/mL ≥ 6 month precede screen visit ( measure least twice use assay ) . In precede 6 month prior screen , one episode `` blip '' ( HIV1 RNA &gt; 50 &lt; 400 copies/mL ) acceptable , HIV1 RNA &lt; 50 copies/mL immediately `` blip '' . Plasma HIV1 RNA level &lt; 50 copies/mL screen visit Adequate renal function Estimated glomerular filtration rate ≥ 30 mL/min accord CockcroftGault formula ( eGFRCG ) ARVs appropriately dose adjust renal function per package insert All document historical plasma genotype ( ) must show resistance TDF FTC , include , limited presence reverse transcriptase resistance mutation K65R , K70E , M184V/I , thymidine analogassociated mutation ( TAMs ) include M41L , L210W , D67N , K70R , T215Y/F , K219Q/E/N/R . If historical plasma prior first ART available individual 3 ART regimen , individual proviral genotype analysis prior Day 1 confirm absence archive resistance TDF FTC . Study perform DXA scan Tscore receive prior Day 1 Key Previous use approve experimental integrase strand transfer inhibitor ( INSTI ) ( length time ) current regimen contains PI/r Individuals evidence previous virologic failure PI/r INSTIbased regimen ( without resistance either class ARV ) A new AIDSdefining condition diagnose within 30 day prior screen ( except CD4+ cell count and/or percentage criterion ) Hepatitis C virus would require therapy study Individuals receive ongoing treatment bone disease ( eg , osteoporosis ) , include bisphosphonates , denosumab , strontium ranelate NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV 1 Infection</keyword>
	<keyword>HIV</keyword>
	<keyword>Virologically-Suppressed</keyword>
</DOC>